VivoSeq
Other

Postoperative Adjuvant Therapy

0

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Postoperative Adjuvant Therapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Not yet recruiting3 · 50%
Completed2 · 33%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06685289·70 enrolled
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT06238167·40 enrolled
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Not yet recruiting·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 4·NCT07160361·56 enrolled
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330076·28 enrolled
Postoperative Adjuvant Therapy of HCC Based on PD-1
Completed·—·N/A·NCT05307926·573 enrolled
Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC
Completed·TThe University of Hong Kong·Phase 1/2·NCT00234182·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)